Symptoms and General Pathology

All Conditions

Genetic Predisposition to Disease

Disease Susceptibility

Disease Attributes

The saliva samples will be made of selected related (DNA).

salivary kit

Sandrine CAPUTO, PhD

Isabelle TURBIEZ, Project Manager

Emmanuelle FOURME, PhD

Emmanuelle FOURME, MD

Dominique STOPPA-LYONNET, PU-PH

Gilles MORIN, MD

Marie COUDERT, MD

Stéphanie CHIEZE-VALERO, MD

Hélène DREYFUS, MD

Marie-Agnès COLLONGE-RAME, MD

Julie TINAT, MD

Virginie BUBIEN, MD

Isabelle MORTEMOUSQUE, MD

Marc PLANES, MD

Pascaline BERTHET, MD

Sandra FERRER, MD

Mathilde GAY-BELLILE, MD

Jean-Marc LIMACHER

Jean-Marc LIMACHER, MD

Laurence FAIVRE-OLIVIER, MD

Clémentine LEGRAND, MD

Elodie LACAZE, MD

Audrey MAILLIEZ, MD

Sophie LEJEUNE, MD

Laurence VENAT-BOUVET, MD

Sophie GIRAUD, MD

Christine LASSET, MD

Hagay SOBOL, PhD

Hélène ZATTARA, MD

Isabelle COUPIER, MD

Alain LORTHOLARY, MD

Véronique MARI, MD

Jean CHIESA, MD

E COTTEREAU, MD

Antoine DARDENNE, MD

Véronica CUSIN, MD

Clémence EVREVIN, MD

Odile COHEN-HAGUENAUER, MD

Pierre-Laurent PUIG, Phd

Anne DURLACH, MD

Fanny BRAYOTEL, MD

Tan Dat NGUYEN, PHD

Louise CRIVELLI, MD

Isabelle TENNEVET, MD

Capucine DELNATTE, MD

Fabienne PRIEUR, MD

Philippe BOUDIER, MD

Christine MAUGARD, MD

Laurence GLADIEFF, MD

Charlotte CAILLE-BENIGNI, MD

Marie-Noëlle BONNET-DUPEYRON, MD

Jean-Marie RAVEL, MD

Olivier CARON, MD

Marilyn LACKMY-PORT-LIS, MD

Odile BERA, MD

Hanitra RANJATOELINA, MD

The aim of the COVAR project is to classify reliably a maximum of VUS of the French database in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some cases to propose a prophylactic surgery.

Originally, the COVAR study was designed to explore Variants of unknown biological significance (VUS) in BRCA1 (BReast Cancer 1) and BRCA2 (BReast Cancer 2) genes, which are the two major genes identified in hereditary breast and/or ovarian cancers. Since then the study has evolved, in parallel with the evolution of diagnosis, first introducing the PALB2 (Partner and localizer of BRCA2) gene explored in diagnosis since 2015 and now opening the study to all the genes of the panels performed in diagnosis in families with a genetic predisposition syndrome to cancers.

The French UMD (Universal Mutation Database)-BRCA1/2, accredited by the French National Cancer Institute, collects anonymous results of genetic tests performed by authorized French laboratories since 1995, giving a real-time vision of families carrying the same VUS. In september 2011, the French UMD-BRCA1/2 database comprised 706 different variants in 1,300 BRCA1 families and 1,089 different variants in 2,101 BRCA2 families. In April 2021, this database contained 1,651 different VSU for BRCA1, 3,015 different VUS for BRCA2, 471 different VUS for PALB2, 68 for RAD51C and 66 for RAD51D.

Since 2017, new genes have been explored in the diagnostic setting as they have been reported as predisposing factors for cancers. This list is constantly evolving (Moretta et al., 2018; Dhooge et al., 2020). Data collection for these genes is ongoing and a new database (FrOG) gathering all VUS and mutations identified in the French oncogenetic network has been set up. We have set up a consortium agreement at the end of 2020. This database gathers to date 12 genes and 11,912 different variants in more than 40,000 French families.

One of the key measurable parameters for classification of VUS as causal mutations is their co-segregation with the disease. The average size of French families is relatively small, the information of variant co-segregation limited to one family would not be significant. However, the compilation of co-segregation results obtained from several families will allow to obtain more precise and complete estimations of the probability of causality of a given variant.

The objective of the COVAR study (COsegregation VARiants) is to organize co-segregation studies of the VUS of the database UMD-BRCA1/2, in order to determine the causal or non-causal nature of these variants. To organize the variants by their clinical relevance, a grid with 5 classes has been used: 1=neutral, 2=likely neutral, 3=VUS, 4=likely causal, 5=causal. The VUS of classes 3 and 4 will be candidates to co-segregation studies because they cannot be used for the genetic counseling.

In the selected families the index case will invite the family members (affected and unaffected) to provide a sample of salivary fluid to test the presence of the VUS. The probability that a VUS is causal will be calculated from the cosegregation data using a Bayesian model. The results will be integrated in the multifactorial model described by D. Goldgar, model integrating different parameters as amino acid conservation, structural impact of the variant, co-occurrence with a pathogenic mutation, family history and tumor characteristics.

COsegregation of VARiants in Panel of Genes

Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling

Institut Curie

Spots Global Cancer Trial Database for salivary kit

Every month we try and update this database with for salivary kit cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.